IP Library Assignment 025105/0517
Patent Assignment
Reel/Frame 025105/0517

Assignment of Assignor's Interest

Recorded: 2010-10-07 Pages: 5
Assignor
NOVOZYMES BIOPHARMA UK LIMITED
Executed: 2009-08-13
Assignee
NOVOZYMES BIOPHARMA DK A/S
KROGSHOEJVEJ 36, BAGSVAERD, DK-2880, DENMARK
Covered Properties (12)
Fusion Polypeptides Comprising Human Serum Albumin,Nucleic Acids Encoding Same,and Recombinant Expression Thereof
Patent: 5,876,969 →
Application: 08/797,689 →
Fusion Polypeptides of Human Serum Albumin and a Therapeutically Active Polypeptide
Patent: 6,686,179 →
Application: 09/984,186 →
Publication: US 2002/0151011
Hormone and Albumin Fusion Protein
Patent: 7,056,701 →
Application: 10/237,624 →
Publication: US 2003/0082747
G-Csf and Albumin Fusion Protein
Patent: 7,041,478 →
Application: 10/237,667 →
Publication: US 2003/0022308
Interleukin and Albumin Fusion Protein
Patent: 7,081,354 →
Application: 10/237,708 →
Publication: US 2003/0036170
Interferon and Albumin Fusion Protein
Patent: 6,972,322 →
Application: 10/237,866 →
Publication: US 2003/0036171
Insulin and Albumin Fusion Protein
Patent: 7,094,577 →
Application: 10/237,871 →
Publication: US 2003/0036172
Methods of Treatment with Erythropoietin and Albumin Fusion Protein
Patent: 6,989,365 →
Application: 10/702,536 →
Publication: US 2004/0086976
Erythropoietin and Albumin Fusion Protein, Nucleic Acids, and Met Hods Thereof
Patent: 6,987,006 →
Application: 10/702,636 →
Publication: US 2004/0086977
Methods of Treatment with Interferson and Albumin Fusion Protein
Patent: 7,435,410 →
Application: 11/146,077 →
Publication: US 2005/0239167
Fusion Polypeptides of Human Serum Albumin and a Therapeutically Active Polypeptide
Patent: 7,410,779 →
Application: 11/330,353 →
Publication: US 2006/0105429
Methods of Treating Using Hormone-Albumin Fusion Proteins
Patent: 7,833,521 →
Application: 11/927,628 →
Publication: US 2009/0176276
Related Assignments (8)
Other recorded transfers of the patents in this record — the chain of ownership.
Contract Mar 1, 2002
From: RHONE-POULENC RORER S.A.
To: CENTEON L.L.C.
Reel/Frame 012653/0458 →
Change of Name Mar 11, 2002
From: CENTEON L.L.C.
To: AVENTIS BEHRING L.L.C.
Reel/Frame 012698/0406 →
Assignment of Assignor's Interest Jul 11, 2006
From: AVENTIS BEHRING L.L.C.
To: DELTA BIOTECHNOLOGY LTD.
Reel/Frame 017921/0492 →
Change of Name Dec 31, 2007
From: NOVOZYMES DELTA LIMITED
To: NOVOZYMES BIOPHARMA UK LIMITED
Reel/Frame 020299/0491 →
Change of Name Dec 31, 2007
From: DELTA BIOTECHNOLOGY LIMITED
To: NOVOZYMES DELTA LIMITED
Reel/Frame 020299/0814 →
Corrective Assignment to Correct the U.S. Patent No. 6,686,179 Was Erroneously Typed as U.S. Patent No. 6,684,179 Previously Recorded on Reel 020299 Frame 0491. Assignor(S) Hereby Confirms the Change of Name. May 30, 2008
From: NOVOZYMES DELTA LIMITED
To: NOVOZYMES BIOPHARMA UK LIMITED
Reel/Frame 021018/0539 →
Corrective Assignment to Correct the U.S. Patent No. 6,686,179 Was Erroneously Typed as U.S. Patent No. 6,684,179 Previously Recorded on Reel 020299 Frame 0814. Assignor(S) Hereby Confirms the Change of Name. May 30, 2008
From: DELTA BIOTECHNOLOGY LIMITED
To: NOVOZYMES DELTA LIMITED
Reel/Frame 021018/0534 →
Corrective Assignment to Correct the U.S. Patent No. 6,686,179 Was Erroneously Typed as U.S. Patent No. 6,684,179 Previously Recorded on Reel 017921 Frame 0492. Assignor(S) Hereby Confirms the Change of Name. May 30, 2008
From: AVENTIS BEHRING L.L.C.
To: DELTA BIOTECHNOLOGY LIMITED
Reel/Frame 021018/0510 →